Trump's Drug Pricing Strategy: An Analysis of Recent Developments

President Donald Trump's administration has launched a series of initiatives aimed at reducing pharmaceutical prices in the United States. Central to this effort is the "Most-Favored-Nation" (MFN) pricing model, which mandates that drug manufacturers offer U.S. patients prices no higher than those available in other developed countries. Recent agreements with major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck KGaA, have been established to implement this pricing strategy.

Inside the MFN Pricing ActionsForbesForbesPharma companies announce direct-to-consumer sales and price cuts in USInvestopedia

In late September 2025, Pfizer announced a deal to provide Medicaid patients with drugs at prices comparable to those in other developed nations, in exchange for a three-year exemption from tariffs on pharmaceuticals. This agreement includes a commitment to invest $70 billion in U.S. manufacturing and research. AstraZeneca followed suit with a similar arrangement, promising discounts of up to 80% on select drugs and a $50 billion investment in U.S. operations.

ForbesForbesPharma companies announce direct-to-consumer sales and price cuts in USInside the MFN Pricing ActionsPharmaphorum

Merck KGaA's U.S. subsidiary, EMD Serono, has also joined the initiative, agreeing to sell fertility drugs at an 84% discount through the upcoming TrumpRx direct-to-consumer platform, set to launch in early 2026. This platform aims to provide patients with direct access to discounted medications, bypassing traditional pharmacy channels.

FiercePharma

Despite these agreements, experts express skepticism regarding the actual impact on drug prices. Economists, including Geoffrey Joyce from the University of Southern California, argue that Medicaid already pays prices similar to those in Europe, suggesting that the MFN policy may not lead to significant changes. Harvard professors Amar H. Kelkar and Edward R. Scheffer Cliff have noted that legal and operational barriers could hinder the effectiveness of the MFN policy.

Investopedia

Furthermore, the proposed tariffs on pharmaceutical imports, which could reach 100%, may inadvertently raise drug prices for consumers. Analysts predict that these tariffs could lead to increased costs for generic drugs and domestically manufactured products, as companies adjust their pricing strategies in response to the new economic landscape.

Investopedia100% U.S. Drug Tariffs: Implications For Pharma And OutsourcingInside the MFN Pricing ActionsForbesPharma companies announce direct-to-consumer sales and price cuts in US

Critics of the MFN pricing model argue that it may lead to unintended consequences, such as pharmaceutical companies withdrawing their products from foreign markets to avoid price reductions. Additionally, there are concerns that the emphasis on price reductions could undermine the value of innovative treatments, particularly for vulnerable populations, including the elderly and disabled.

Inside the MFN Pricing Actions

Some industry experts have called for a more collaborative approach, suggesting that the administration should support the pharmaceutical industry in establishing fair global pricing rather than imposing ultimatums.

Forbes

The Trump administration's drug pricing strategy is still evolving, with upcoming developments expected as the TrumpRx platform prepares for launch. As negotiations continue with pharmaceutical companies, the effectiveness of these initiatives in lowering drug prices for American consumers remains to be seen.

ForbesForbesPharma companies announce direct-to-consumer sales and price cuts in USInvestopediaInside the MFN Pricing Actions

• “Although the MFN policy correctly captures the urgency of addressing unaffordable U.S. drug prices, it is unlikely to meaningfully reduce prices due to legal, operational, and market barriers,” — Amar H. Kelkar and Edward R. Scheffer Cliff, Harvard Professors

Investopedia

• “We must modernize the review process and try new approaches to meet the needs of the American people,” — Marty Makary, FDA Commissioner

Forbes

• “This new approach also helps safeguard America’s pioneering role as a global powerhouse in innovation,” — Pascal Soriot, CEO of AstraZeneca

Forbes

• “We want to make it easier for all couples to have babies, raise children and have the families they have always dreamed about,” — Donald Trump, President of the United States

Forbes

There is a discrepancy among experts regarding the potential impact of the MFN pricing model. While some believe it will lead to significant price reductions, others argue that existing pricing structures may remain largely unchanged. Additionally, the long-term effects of proposed tariffs on drug prices have yet to be fully assessed.

Forbes